Suvratoxumab (MEDI4893) 是一种长效且具有亲和力高的人源化抗 α-毒素单克隆抗体(IgG1κ 型)。Suvratoxumab 能有效中和 α-毒素 (一种关键的金黄色葡萄球菌毒力因子)。Suvratoxumab 可提高免疫功能低下的小鼠肺炎模型的存活率并减少肺损伤。Suvratoxumab 还可增强 Vancomycin (HY-B0671) 或 Linezolid (HY-10394) 的抗菌活性。
| 生物活性 | Suvratoxumab (MEDI4893) is a long-acting, high-affinityhumanized anti-α-toxin monoclonal antibody(IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a keyS. aureusvirulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity ofVancomycin(HY-B0671) orLinezolid(HY-10394)[1][2][3]. |
| IC50& Target | α-toxin of S. aureus[1][2][3]. |
体内研究
(In Vivo) | Suvratoxumab (5, 15, 45 mg/kg; i.p.; single) increases survival rates in an immunocompromised murine pneumonia model[1].
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis reduces pulmonary damage and increases macrophage phagocytosis in mice[1].
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis improves the effectiveness of antibiotic (vancomycin or linezolid) treatment in mice[1].
| Animal Model: | Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. | | Dosage: | 5, 15, 45 mg/kg | | Administration: | Intraperitoneal injection; single | | Result: | Resulted in dose-dependent increases in survival rates and reductions in bacterial CFU. |
| Animal Model: | Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. | | Dosage: | 15 mg/kg | | Administration: | Intraperitoneal injection; single | | Result: | Prophylaxis protected the lungs ofS. aureus-infected immunocompromised mice from α toxin-mediated damage. |
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com